Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.

16 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020 is safe and effective in improving schizophrenia, in addition to improving cognitive impairment associated with this condition.

28 Sep 2012

ARIAD Pharmaceuticals completes rolling submission of ponatinib NDA with FDA

ARIAD Pharmaceuticals, Inc. today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).

28 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

MD Anderson introduces Moon Shots Program to reduce cancer deaths

The University of Texas MD Anderson Cancer Center announces the launch of the Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths.

21 Sep 2012

Strand Life Sciences to validate and commercialize Trovagene's urine-based HPV test

Trovagene, Inc. and Strand Life Sciences Pvt Ltd., of Bangalore, India, completed their agreement to validate and commercialize Trovagene's proprietary urine-based Human Papillomavirus (HPV) test for clinical diagnostic and carrier screening use.

21 Sep 2012

MRD monitoring falls short in childhood AML assessment

Measuring treatment response by minimal residual disease monitoring offers no more prognostic value than morphologic analysis in children with acute myeloid leukemia (AML), show study findings.

19 Sep 2012

Reduced-intensity benefits confirmed for AML cell transplantation

Reduced-intensity conditioning reduces toxicity associated with allogeneic hematopoietic cell transplantation for acute myeloid leukemia without affecting long-term outcomes, show results from the first randomized trial of this treatment.

19 Sep 2012

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

13 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

Researchers discover small DNA sequence that drives GATA2 protein

The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.

11 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012